Lysogene Pushes Forward With Sanfilippo Syndrome Study, Establishes Footprint in U.S. Post author:Sam Post published:October 24, 2017 Post category:BioPharma Finding a treatment for Sanfilippo Syndrome is a personal matter for the Lysogene team. Source: BioSpace You Might Also Like COO and First Employee of Editas Medicine to Exit, Effective March 31 March 5, 2017 This Boston Biotech Gets $57.5 Million Upfront, $2.1 Billion Commitment From Drug Giant AstraZeneca PLC May 2, 2017 La Jolla Pharma Announces Financial Results For The Three And Six Months Ended June 30, 2017 And Recent Corporate Progress July 27, 2017
This Boston Biotech Gets $57.5 Million Upfront, $2.1 Billion Commitment From Drug Giant AstraZeneca PLC May 2, 2017
La Jolla Pharma Announces Financial Results For The Three And Six Months Ended June 30, 2017 And Recent Corporate Progress July 27, 2017
